Oxiconazole|CAS 64211-46-7|DC Chemicals

Cas No.:	64211-46-7
Chemical Name:	(Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid
Synonyms:	Oxiconazole, Oxistat, Oxizole, Fonx, Myfungar; Ro 13-8996; Ro-13-8996; Ro13-8996; Sgd 301-76; ST 813; ST-813; ST813;
SMILES:	C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-]
Formula:	C₁₈H₁₄Cl₄N₄O₄
M.Wt:	492.1402
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Oxiconazole nitrate is a broad spectrum antifungal which can inhibit the growth of T. tonsurans and T. rubrum with MIC90s of 0.25 and 0.5 μg/mL, respectively.
Target:	MIC90: 0.25 μg/mL (T. tonsurans), 0.5 μg/mL (T. rubrum)[1]
In Vivo:	The baseline distortion product otoacoustic emission (DPOAE) results of the right ears of all animals tested are normal. Animals in groups I, II, IV and V show no statistically significant change in the DPOAE amplitudes. The rats in the gentamicingroup show a significant decrease[2].
In Vitro:	Oxiconazole nitrate is the more active compound in tests with T. tonsurans and T. rubrum. Twelve isolates are inhibited by 0.063 μg/mL of oxiconazole; corresponding econazole MICs range from 0.063 (three isolates) to 8 (two isolates) μg/mL. Three isolates have oxiconazole MICs of 16 or 32 μg/mL[1].
Cell Assay:	A total of 121 isolates of pathogenic fungi are tested. The three drugs (including Oxiconazole nitrate) are serially diluted in sterile saline. For each test plate, 2 mL of a solution of drug in sterile saline is added to an 18 mL blank of molten agar medium at 50°C and mixed well; the resulting mixtures are then poured into the plates and allowed to solidify. The resulting drug dilution sequences range from 128 to 0.063 μg/mL. Control plates are prepared in a similar manner using 2 mL blanks of sterile saline. The plates are then inoculated using a replicator. Incubation is at 30°C for a minimum of 96 hr. The Minimal Inhibitory Concentration (MIC) is defined as the lowest concentration of drug producing complete inhibition of growth[1]
Animal Administration:	Fifty adult rats are divided into 5 groups consisting of 10 animals each. Over 14 days, the rats in group I receive 0.1 mL of Oxiconazole nitrate-containing solution drops, group II receives 4% boric acid solution in alcohol drops, and groups III and IV receive gentamicin (40 mg/mL) and saline solutions, respectively. Group V receives no medication. Each solution used is given twice a day[2].
References:	[1]. Shadomy S, et al. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. [2]. Özdemir S, et al. Effects of topical oxiconazole and boric acid in alcohol solutions to rat inner ears. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1023-7.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.